May 23, 2016

Afimmune announces DS102 will be developed for pulmonary disorders in addition to NASH

Dublin, Ireland, 23rd May, 2016: Afimmune today announced plans to develop its anti-fibrotic and anti-inflammatory compound DS102 in chronic obstructive pulmonary disease (COPD) patients as well […]